INFLAMMATORY BREAST CANCER
Clinical trials for INFLAMMATORY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new INFLAMMATORY BREAST CANCER trials appear
Sign up with your email to follow new studies for INFLAMMATORY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo combo aims to shrink aggressive breast cancer before surgery
Disease control OngoingThis phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo aims to shrink tough breast cancer tumors
Disease control OngoingThis study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Antonio Giordano, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New chemo cocktail shows promise for rare, aggressive breast cancer
Disease control OngoingThis phase 2 study tested a drug called eribulin followed by standard chemotherapy (doxorubicin and cyclophosphamide) as a preoperative treatment for HER2-negative inflammatory breast cancer, a rare and aggressive form of the disease. The goal was to see if this combination could…
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Immunotherapy combo shows promise in aggressive breast cancer trial
Disease control OngoingThis phase II trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy can improve outcomes for people with HER2-negative inflammatory breast cancer, a rare and aggressive type. About 52 participants will receive either chemo alone …
Matched conditions: INFLAMMATORY BREAST CANCER
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 26, 2026 15:40 UTC